CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increased risk of a RAC audit, along with
Labs Have Questions about Prostate Biopsy Policy
By Joseph Burns, from the Volume XIX No. 13 - September 17, 2012 issue